Home › Research › Prevention and risk
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM, Lockery JE et al.. The New England journal of medicine, 2018-09-16
Topic: Risk, prevention and care in population studies
Plain-language summary
Background Aspirin is a well-established therapy for the secondary prevention of cardiovascular events. However, its role in the primary prevention of cardiovascular disease is unclear, especially in older persons, who have an increased risk. Methods From 2010 through 2014, we enrolled community-dwelling men and women in Australia and the United States who were 70 years of age or older (or ≥65 years of age among blacks and Hispanics in the United States) and did not have cardiovascular disease, dementia, or disability. Participants were randomly assigned to receive 100 mg of enteric-coated aspirin or placebo. The primary end point was a composite of death, dementia, or persistent physical disability; results for this end point are reported in another article in the Journal. Secondary end points included major hemorrhage and cardiovascular disease (defined as fatal coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal stroke, or hospitalization for heart failure). Results Of the 19,114 persons who were enrolled in the trial, 9525 were assigned to receive aspirin and 9589 to receive placebo. After a median of 4.7 years of follow-up, the rate of cardiovascular disease was 10.7 events per 1000 person-years in the aspirin group and 11.3 events per 1000 person-years in the placebo group (hazard ratio, 0.95; 95% confidence interval [CI], 0.83 to 1.08). The rate of major hemorrhage was 8.6 events per 1000 person-years and 6.2 events per 1000 person-years, respectively (hazard ratio, 1.38; 95% CI, 1.18 to 1.62; P Conclusions The use of low-dose aspirin as a primary prevention strategy in older adults resulted in a significantly higher risk of major hemorrhage and did not result in a significantly lower risk of cardiovascular disease than placebo. (Funded by the National Institute on Aging and others; ASPREE ClinicalTrials.gov number, NCT01038583 .).
What this study adds
Evidence grade: Low
This is a trial of 19,114 participants. In 19,114 healthy adults aged 70+ (65+ for Black and Hispanic participants in the US), daily 100 mg aspirin did not clearly lower heart attacks, strokes or heart failure over a median 4.7 years (10.7 vs 11.3 events per 1000 person-years; hazard ratio 0.95, 95% CI 0.83 to 1.08). It did raise major bleeding (8.6 vs 6.2 per 1000 person-years; hazard ratio 1.38).
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
McNeil, J. J., Wolfe, R., Woods, R. L., Tonkin, A. M., Donnan, G. A., Nelson, M. R., et al. (2018). Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. The New England journal of medicine. https://doi.org/10.1056/nejmoa1805819
Vancouver
McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. The New England journal of medicine. 2018. doi:10.1056/nejmoa1805819. PMID: 30221597.
BibTeX
@article{mcneil2018-30221597,
author = {McNeil, J. J. and Wolfe, R. and Woods, R. L. and Tonkin, A. M. and Donnan, G. A. and Nelson, M. R. and Reid, C. M. and Lockery, J. E. and others},
title = {{Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly}},
journal = {The New England journal of medicine},
year = {2018},
doi = {10.1056/nejmoa1805819},
pmid = {30221597},
url = {https://doi.org/10.1056/nejmoa1805819}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- However, its role in the primary prevention of cardiovascular disease is unclear, especially in older persons, who have an increased risk.
- The primary end point was a composite of death, dementia, or persistent physical disability; results for this end point are reported in another article in the Journal.
- Results Of the 19,114 persons who were enrolled in the trial, 9525 were assigned to receive aspirin and 9589 to receive placebo.
- The rate of major hemorrhage was 8.6 events per 1000 person-years and 6.2 events per 1000 person-years, respectively (hazard ratio, 1.38; 95% CI, 1.18 to 1.62; P<0.001).
Why it matters
In 19,114 healthy adults aged 70+ (65+ for Black and Hispanic participants in the US), daily 100 mg aspirin did not clearly lower heart attacks, strokes or heart failure over a median 4.7 years (10.7 vs 11.3 events per 1000 person-years; hazard ratio 0.95, 95% CI 0.83 to 1.08). It did raise major bleeding (8.6 vs 6.2 per 1000 person-years; hazard ratio 1.38). The trial's dementia result is reported in a separate paper, so this study offers no evidence that aspirin prevents Alzheimer's.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Participants19,114
- Evidence strengthLow
How this study scored 81/100
Published in a top-tier journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (The New England journal of medicine) |
| Journal's citation record | 4 / 4 | New England Journal of Medicine: journal h-index 1,505 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 4 / 4 | 19,114 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 7 / 7 | Cited 1,140 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 114.0 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 6 / 6 | Cited 95.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 4 / 4 | Cited 306 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Anne M. Murray: h-index 60 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | National Institutes of Health: institution h-index 2,723 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 26 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30221597) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 81 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Prevention and risk from nearby years
Also tagged “palliative”
858 studies in the library carry the topic tag “palliative”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 858 tagged studies.